2 Beaten-Down Stocks to Buy on the Dip
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative medical therapies.CRISPR Therapeutics' shares are down by 41% over the trailing-12-month period, while Merck's have declined by 22%. Though both companies have encountered some headwinds, there are good reasons for patient investors to initiate positions, especially at current levels.It's not hard to figure out why CRISPR Therapeutics, a gene-editing specialist, isn't performing well. Though the company earned approval for Casgevy, which treats a pair of rare blood diseases, in late 2023, it's still not generating much revenue from it. Administering gene-editing therapies is expensive and time-consuming. Furthermore, CRISPR Therapeutics will share the profits generated from Casgevy with Vertex Pharmaceuticals, with which it developed the medicine; Vertex is entitled to 60% of the program profits.Continue reading
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative medical therapies.
CRISPR Therapeutics' shares are down by 41% over the trailing-12-month period, while Merck's have declined by 22%. Though both companies have encountered some headwinds, there are good reasons for patient investors to initiate positions, especially at current levels.
It's not hard to figure out why CRISPR Therapeutics, a gene-editing specialist, isn't performing well. Though the company earned approval for Casgevy, which treats a pair of rare blood diseases, in late 2023, it's still not generating much revenue from it. Administering gene-editing therapies is expensive and time-consuming. Furthermore, CRISPR Therapeutics will share the profits generated from Casgevy with Vertex Pharmaceuticals, with which it developed the medicine; Vertex is entitled to 60% of the program profits.
